Laboratory of Hematology, Haemophilia Center, University Hospital, Nantes, France.
Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):E25-9. doi: 10.1177/1076029610379848. Epub 2010 Aug 19.
We evaluated the use of the turbidimetric HemosIL von Willebrand Factor (VWF) Activity assay (VWF:Act) on the STA-R automated coagulometer (Stago, Asnières, France) for the diagnosis of von Willebrand disease (VWD). For this, we prospectively screened 268 patients. As a second part, we retrospectively assayed 111 patients with well-defined VWD subtype. In the first prospective study, we demonstrate that in most cases of VWD, VWF ristocetin cofactor activity (VWF:RCo) and VWF:Act are highly correlated but that they both cannot be considered a good screening assay when used alone, since they could miss about 25% of VWF abnormalities. However, the association of VWF:Act analysis and the Platelet Function Analyzer-100 (PFA-100) test constitutes an excellent screening strategy. In our second retrospective study concerning VWD subtypes, VWF:RCo and VWF:Act were well correlated but could be very discrepant, especially for some cases of type 2M VWD. We consider that VWF:RCo remains the "reference assay" for VWD subtype classification.
我们评估了基于 STA-R 全自动凝血仪(Stago,Asnières,法国)的比浊法 HemosIL 血管性血友病因子(VWF)活性测定(VWF:Act)在血管性血友病(VWD)诊断中的应用。为此,我们前瞻性筛选了 268 例患者。作为第二部分,我们回顾性分析了 111 例明确诊断为 VWD 亚型的患者。在第一项前瞻性研究中,我们证明在大多数 VWD 病例中,VWF 瑞斯托霉素辅因子活性(VWF:RCo)和 VWF:Act 高度相关,但单独使用时它们都不能作为一种良好的筛选检测方法,因为它们可能会漏诊约 25%的 VWF 异常。然而,VWF:Act 分析与血小板功能分析仪-100(PFA-100)检测联合使用是一种很好的筛选策略。在第二项涉及 VWD 亚型的回顾性研究中,VWF:RCo 和 VWF:Act 相关性良好,但可能存在很大差异,尤其是对于一些 2M 型 VWD 病例。我们认为 VWF:RCo 仍然是 VWD 亚型分类的“参考检测方法”。